General Investigational Service Coverage Exception
SFHP may cover an investigational service when ALL of the following criteria are clearly documented in the member's medical records:
ALL of the following
Conventional therapy will not adequately treat the intended patient's condition.
Conventional therapy will not prevent progressive disability or premature death.
The provider of the proposed service has a record of safety and success with it equivalent or superior to that of other providers of the investigational service.
The investigational service is the lowest-cost item or service that meets the patient's medical needs and is less costly than all conventional alternatives.
The service is not being performed as part of a research study protocol.
There is a reasonable expectation that the investigational service will significantly prolong the intended patient's life or maintain or restore a range of physical and social function suited to activities of daily living.
Care Plus Medicare IDE Study Coverage
Medicare allows payment of the routine cost of care for Medicare beneficiaries in certain categories of Investigational Device Exemption (IDE) studies. Category A and Category B IDE studies require prior authorization and are covered when ALL of the following requirements are met:
ALL of the following
The principal purpose of the study is to test whether the device improves health outcomes of appropriately selected patients.
The rationale for the study is well supported by available scientific and medical information, or the study is intended to clarify or establish the health outcomes of interventions already in common clinical use.
The study results are not anticipated to unjustifiably duplicate existing knowledge.
The study design is methodologically appropriate, and the anticipated number of enrolled subjects is adequate to confidently answer the research question or questions being asked in the study.
External Independent Review Eligibility
A member is eligible for SFHP's external, independent review process for an experimental or investigational therapy only when ALL of the following criteria are met:
ALL of the following
The member has a life-threatening or seriously debilitating condition.
The member's physician certifies that the member has a life-threatening or seriously debilitating condition for which standard therapies have not been effective in improving the member's condition, standard therapies would not be medically appropriate for the member, or there is no more beneficial standard therapy covered by SFHP than the therapy proposed.
ONE of the following
The member's physician, who is contracted with SFHP, has recommended a service, procedure, medical supply, durable medical equipment, or other therapy that the physician certifies in writing is likely to be more beneficial to the member than any available standard therapies.
Terminal Illness Conference Appeal
A member with a terminal illness may request a conference appeal after SFHP denies an experimental or investigational service when ALL of the following conference criteria are met:
ALL of the following
SFHP's representative at the conference is an SFHP Medical Director serving as the staff member with authority to determine the resolution of the appeal.
The member and the member's representative may attend the conference telephonically or in person.
The member is given the opportunity to attend the conference within 30 calendar days of the denied authorization.
If the member's treating physician determines, after consultation with SFHP's Medical Director and based on standard medical practice, that the effectiveness of the proposed treatment would be materially reduced if it is not provided at the earliest possible date, the conference is held within five business days.
SFHP does not cover investigational or experimental services. This exclusion does not apply to services related to qualifying clinical trials for the prevention, detection, or treatment of cancer or other life-threatening diseases or conditions outlined in CO-47: Clinical Trials.
SFHP may cover investigational services under 22 CCR section 51303(h) when all applicable documentation and clinical criteria are met, as described above.
This policy pertains to the Clinical Operations Department's process for evaluating medical services as investigational or experimental in nature. Refer to Pharm-02: Pharmacy Prior Authorization for the Pharmacy Department's evaluation of pharmaceuticals.
Investigational or experimental services do not meet the criteria for medically necessary services because they are not standard medical practice.
Services are investigational or experimental if any of the following apply: the requested service does not have unrestricted FDA market approval or final approval from another governmental regulatory body for treatment of a specified condition; there is insufficient or inconclusive medical and scientific evidence to evaluate the therapeutic value of the service; peer-reviewed medical literature provides inconclusive evidence that the service, procedure, medical supply, or durable medical equipment beneficially affects health outcomes; the service, procedure, medical supply, or durable medical equipment is not as beneficial as an established alternative; or there is insufficient information or inconclusive scientific evidence that, when used in a non-investigational setting, the service beneficially affects health outcomes or is as beneficial as an established alternative.
Adequate evidence is defined as at least two documents of medical and scientific evidence indicating that the proposed treatment is likely to benefit the member. Interim approval granted as a step in the regulatory process does not substitute for final or unrestricted market approval.